Suppr超能文献

药理学定义的α1A-与克隆的α1C-肾上腺素能受体等同的功能证据:大鼠离体灌注肾研究。

Functional evidence equating the pharmacologically-defined alpha 1A- and cloned alpha 1C-adrenoceptor: studies in the isolated perfused kidney of rat.

作者信息

Blue D R, Bonhaus D W, Ford A P, Pfister J R, Sharif N A, Shieh I A, Vimont R L, Williams T J, Clarke D E

机构信息

Syntex Research, Palo Alto, CA 94304, USA.

出版信息

Br J Pharmacol. 1995 May;115(2):283-94. doi: 10.1111/j.1476-5381.1995.tb15875.x.

Abstract
  1. The present study characterizes and classifies alpha 1-adrenoceptor-mediated vasoconstriction in the isolated perfused kidney of rat using quantitative receptor pharmacology and compares the results to radioligand binding studies (made in cloned alpha 1-adrenoceptor subtypes, native alpha 1A-adrenoceptors in submaxillary gland of rat, and alpha 1A-adrenoceptors in several other tissues of rat). 2. Concentration-effect curves to noradrenaline in the presence of 5-methyl-urapidil were biphasic, indicating alpha 1-adrenoceptor heterogeneity. The alpha 1-adrenoceptor subtype mediating the first phase (low affinity for 5-methyl-urapidil) could not be 'isolated' for detailed pharmacological characterization but was defined by a sensitivity to inhibition by chloroethylclonidine and an inability of methoxamine to activate the site. Additionally, vasoconstriction mediated by this alpha 1-adrenoceptor subtype or subtypes was abolished by nitrendipine (1 microM), thereby allowing characterization of the second, high affinity site for 5-methyl-urapidil. 3. The following antagonists interacted competitively with noradrenaline at the alpha 1-adrenoceptor for which 5-methyl-urapidil exhibits high affinity (pKB value): WB 4101 (10.3) > prazosin (9.5) approximately HV 723 (9.3) approximately 5-methyl-urapidil (9.2) > phenotolamine (8.6) > spiperone (pA2 = 8.1) approximately oxymetazoline (7.9). In contrast, insurmountable antagonism was seen with S(+)- and R(-)-niguldipine, the S(+)-isomer being approximately 30 fold more potent than the R(-)-isomer. Receptor protection experiments indicated that S(+)-niguldipine interacted directly with alpha 1-adrenoceptors. Dehydroniguldipine acted as a competitive antagonist (pKB = 9.0). Thus, the results with antagonists define the alpha 1-adrenoceptor as an alpha 1A-adrenoceptor. 4. An agonist 'fingerprint' was constructed in the presence of nitrendipine to define further the alpha 1A-adrenoceptor. The following order and relativity of agonist potency was obtained: cirazoline (1) approximately adrenaline (2) > noradrenaline (5) > phenylephrine (23) approximately amidephrine (31) > methoxamine (71) >> isoprenaline (1456) approximately dopamine (2210). 5. A high correlative association was shown between the affinity of antagonists obtained functionally in the isolated perfused kidney of rat and pKi values obtained from binding experiments with the cloned bovine alpha 1C-adrenoceptor (R2 = 0.85), native alpha 1A-adrenoceptors in submaxillary gland of rat (R2 = 0.79), and alpha 1A-adrenoceptors from several other tissues of rat (values taken from the literature, R2 = 0.89). 6. The present study demonstrates that the alpha 1A-adrenoceptor is the predominant alpha 1-adrenoceptor subtype mediating vasoconstrictor responses to exogenously administered noradrenaline in the isolated perfused kidney of rat. More importantly, alpha 1A-adrenoceptors mediating vasoconstrictor responses to noradrenaline exhibited a pharmacological equivalency to the cloned bovine alpha 1 c-adrenoceptor. Thus,definitive functional pharmacological data are provided for equating the two receptors and support results derived recently from molecular and radioligand binding studies.
摘要
  1. 本研究运用定量受体药理学方法,对大鼠离体灌注肾中α1 - 肾上腺素能受体介导的血管收缩进行了表征和分类,并将结果与放射性配体结合研究(针对克隆的α1 - 肾上腺素能受体亚型、大鼠颌下腺中的天然α1A - 肾上腺素能受体以及大鼠其他几种组织中的α1A - 肾上腺素能受体)进行了比较。2. 在5 - 甲基 - 乌拉地尔存在的情况下,去甲肾上腺素的浓度 - 效应曲线呈双相,表明存在α1 - 肾上腺素能受体异质性。介导第一相(对5 - 甲基 - 乌拉地尔低亲和力)的α1 - 肾上腺素能受体亚型无法“分离”以进行详细的药理学表征,但可通过对氯乙可乐定抑制的敏感性以及甲氧明无法激活该位点来定义。此外,尼群地平(1μM)可消除由该α1 - 肾上腺素能受体亚型或多种亚型介导的血管收缩,从而得以表征5 - 甲基 - 乌拉地尔的第二个高亲和力位点。3. 以下拮抗剂在5 - 甲基 - 乌拉地尔表现出高亲和力的α1 - 肾上腺素能受体处与去甲肾上腺素竞争性相互作用(pKB值):WB 4101(10.3)>哌唑嗪(9.5)≈HV 723(9.3)≈5 - 甲基 - 乌拉地尔(9.2)>酚妥拉明(8.6)>螺哌隆(pA2 = 8.1)≈羟甲唑啉(7.9)。相比之下,S( + ) - 和R( - ) - 尼伐地平表现出不可克服的拮抗作用,S( + ) - 异构体的效力约为R( - ) - 异构体的30倍。受体保护实验表明S( + ) - 尼伐地平直接与α1 - 肾上腺素能受体相互作用。脱氢尼伐地平表现为竞争性拮抗剂(pKB = 9.0)。因此,拮抗剂的结果将α1 - 肾上腺素能受体定义为α1A - 肾上腺素能受体。4. 在尼群地平存在的情况下构建了激动剂“指纹图谱”,以进一步定义α1A - 肾上腺素能受体。获得了以下激动剂效力顺序和相对关系:可乐唑啉(1)≈肾上腺素(2)>去甲肾上腺素(5)>去氧肾上腺素(23)≈间胺肾上腺素(31)>甲氧明(71)>>异丙肾上腺素(1456)≈多巴胺(2210)。5. 在大鼠离体灌注肾中通过功能获得的拮抗剂亲和力与从克隆的牛α1C - 肾上腺素能受体结合实验(R2 = 0.85)、大鼠颌下腺中的天然α1A - 肾上腺素能受体(R2 = 0.79)以及大鼠其他几种组织中的α1A - 肾上腺素能受体(取自文献的值,R2 = 0.89)获得的pKi值之间显示出高度相关的关联。6. 本研究表明,α
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6da/1908326/eeed042d1407/brjpharm00185-0084-a.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验